Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients

被引:0
|
作者
QIU Kui [1 ]
TIAN Hui [2 ]
WANG Wei [2 ]
HU Xiao-peng [2 ]
LI Xiao-bei [2 ]
GONG Li-li [3 ]
LUO Wei [3 ]
LIU Li-hong [3 ]
ZHANG Xiao-dong [2 ]
YIN Hang [2 ]
机构
[1] Department of Pharmacology Beijing Chao-Yang Hospital,Capital Medical University
[2] Kidney Transplantation Program,Department of Urology,Beijing Chao-Yang Hospital,Capital Medical University
[3] Department of Pharmacology,Beijing Chao-Yang Hospital,Capital Medical University
关键词
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
Background Mycophenolic acid(MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation.This study aimed to investigate the pharmacokinetic(PK) characteristics of enteric-coated mycophenolate sodium(EC-MPS) and area under the curve(AUC) from 0 to 12 hours with limited sampling strategies(LSSs) in Chinese renal transplant recipients. Methods This study was conducted in 10 Chinese renal transplant patients receiving living donor and treated with EC-MPS,cyclosporine,and corticosteroids.MPA concentrations were measured by enzyme multiplied immunoassay technique(EMIT).Whole 12-hour PK profiles were obtained on Day 4 after operation.LSSs with jackknife technique, multiple stepwise regression analysis,and Bland-Altman analysis were developed to estimate MPAAUC. Results The mean maximum plasma concentration,the mean time for it to reach peak(T;),and the mean MPA AUC were(11.38±2.49) mg/L,(4.85±3.32) hours,and(63.19±13.54) mgh·L;,respectively.Among the 10 profiles,MPA AUC of four patients was significantly higher than that of the other six patients,and the corresponding T;was significantly longer than that of the other six patients.No patient exhibited a second peak caused by enterohepatic recirculation.The best models were as follows-.27.46±0.94C;±3.24C;±2.81C;(r;=0.972),which was used to predict AUC of fast metabolizer with a mean prediction error(MPE) of -0.21%and a mean absolute prediction error(MAE) of 2.59%; 36.65±3.08C;±5.30C;-4.04C;(r;=0.992),which was used to predict AUC of slow metabolizer with a MPE of 0.58%and a MAE of 1.95%. Conclusions The PKs of EC-MPS had a high variability among Chinese renal transplant recipients.The preliminary PK data indicated the existence of slow and fast metabolizer.These findings may be associated with the enterohepatic recirculation.
引用
收藏
页码:4226 / 4232
相关论文
共 50 条
  • [41] Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: Conversion to enteric-coated mycophenolate sodium
    Calvo, N.
    Sanchez-Fructuoso, A. I.
    Conesa, J.
    Moreno, A.
    Barrientos, A.
    [J]. TRANSPLANTATION PROCEEDINGS, 2006, 38 (08) : 2396 - 2397
  • [42] Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing
    Cooper, Matthew
    Salvadori, Maurizio
    Budde, Klemens
    Oppenheimer, Frederic
    Sollinger, Hans
    Zeier, Martin
    [J]. TRANSPLANTATION REVIEWS, 2012, 26 (04) : 233 - 240
  • [43] Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients
    Patrick Niaudet
    Marina Charbit
    Chantal Loirat
    Anne-Laure Lapeyraque
    Michel Tsimaratos
    Mathilde Cailliez
    Michel Foulard
    Maud Dehennault
    Pierre Marquet
    Kamel Chaouche-Teyara
    Djamila Lemay
    [J]. Pediatric Nephrology, 2009, 24 : 395 - 402
  • [44] Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients
    Chang, HR
    Lin, CC
    Lian, JD
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (05) : 2066 - 2068
  • [45] LONG-TERM SAFETY OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT RECIPIENTS
    Neumayer, Hans H.
    [J]. NEPHROLOGY, 2005, 10 : A213 - A213
  • [46] Enteric-Coated Mycophenolate Sodium Reduces Gastrointestinal Symptoms in Renal Transplant Patients
    Burg, M.
    Saeemann, M. D.
    Wieser, C.
    Kramer, S.
    Fischer, W.
    Lhotta, K.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4159 - 4164
  • [47] Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients
    Niaudet, Patrick
    Charbit, Marina
    Loirat, Chantal
    Lapeyraque, Anne-Laure
    Tsimaratos, Michel
    Cailliez, Mathilde
    Foulard, Michel
    Dehennault, Maud
    Marquet, Pierre
    Chaouche-Teyara, Kamel
    Lemay, Djamila
    [J]. PEDIATRIC NEPHROLOGY, 2009, 24 (02) : 395 - 402
  • [48] Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus
    Bongiorno, Maria Rita
    Pistone, Giuseppe
    Doukaki, Spyridoula
    Arico, Mario
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2010, 49 (06) : 693 - 699
  • [49] Comparison of Inosine-Monophosphate-Dehydrogenase Activity in Patients With Enteric-Coated Mycophenolate Sodium or Mycophenolate Mofetil After Renal Transplantation
    Rath, T.
    Kuepper, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (06) : 2524 - 2528
  • [50] Treatment of bullous pemphigoid with enteric-coated mycophenolate sodium
    Tursen, U.
    Guney, A.
    Kaya, T.
    Ikizoglu, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (04) : 542 - 544